[The use of stalevo in the treatment of patients with Parkinson's disease].

Abstract

OBJECTIVE:

To assess the efficacy and tolerability of the three component drug stalevo in the treatment of patients with Parkinson's disease (PD).

MATERIAL AND METHODS:

We analyzed the experience of using the antiparkinsonian drug stalevo (levodopa/carbidopa/entacapone) in the treatment of acute stages of PD and elderly patients with restricted possibilities of using other antiparkinsonian drugs. The study included 47 patients. A clinical example is presented. RESULTS AND СONCLUSION: Stalevo increased motor and daily activities, reduced the severity of basic symptoms of PD and improved quality of life of the patients.

• Authors: A S Kretova, A V Lyubimov
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 114 Issue 10 Pg. 35-8 ( 2014) ISSN: 1997-7298 [Print] Russia (Federation)
• PMID: 25591514 (Publication Type: Case Reports, Clinical Trial, English Abstract, Journal Article)

Chemical References

• Antiparkinson Agents
• Catechols
• Drug Combinations
• Stalevo
• Levodopa
• Carbidopa

Topics

• Aged
• Antiparkinson Agents (adverse effects, therapeutic use)
• Carbidopa (adverse effects, therapeutic use)
• Catechols (adverse effects, therapeutic use)
• Drug Combinations
• Female
• Humans
• Levodopa (adverse effects, therapeutic use)
• Male
• Middle Aged
• Parkinson Disease (drug therapy)